These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

419 related articles for article (PubMed ID: 21715702)

  • 41. Dopamine agonists for restless legs syndrome.
    Scholz H; Trenkwalder C; Kohnen R; Riemann D; Kriston L; Hornyak M
    Cochrane Database Syst Rev; 2011 Mar; 2011(3):CD006009. PubMed ID: 21412893
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long-term open-label study of pramipexole in patients with primary restless legs syndrome.
    Inoue Y; Kuroda K; Hirata K; Uchimura N; Kagimura T; Shimizu T
    J Neurol Sci; 2010 Jul; 294(1-2):62-6. PubMed ID: 20451927
    [TBL] [Abstract][Full Text] [Related]  

  • 43. L-DOPA/carbidopa for nocturnal movement disorders in uremia.
    Walker SL; Fine A; Kryger MH
    Sleep; 1996 Apr; 19(3):214-8. PubMed ID: 8723378
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Efficacy and safety of pramipexole in chinese patients with restless legs syndrome: results from a multi-center, randomized, double-blind, placebo-controlled trial.
    Ma JF; Wan Q; Hu XY; Sun SG; Wang WZ; Zhao ZX; Wang YJ; Liu CF; Li JM; Jiang YP; Chen SD
    Sleep Med; 2012 Jan; 13(1):58-63. PubMed ID: 22137119
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Efficacy of Pramipexole for the Treatment of Primary Restless Leg Syndrome: A Systematic Review and Meta-analysis of Randomized Clinical Trials.
    Liu GJ; Wu L; Lin Wang S; Xu LL; Ying Chang L; Fu Wang Y
    Clin Ther; 2016 Jan; 38(1):162-179.e6. PubMed ID: 26572941
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Treatment of periodic leg movement disorder and restless leg syndrome with talipexole.
    Inoue Y; Mitani H; Nanba K; Kawahara R
    Psychiatry Clin Neurosci; 1999 Apr; 53(2):283-5. PubMed ID: 10459713
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Night-to-night variability in periodic leg movements in patients with restless legs syndrome.
    Sforza E; Haba-Rubio J
    Sleep Med; 2005 May; 6(3):259-67. PubMed ID: 15854857
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pramipexole: in restless legs syndrome.
    McCormack PL; Siddiqui MA
    CNS Drugs; 2007; 21(5):429-37; discussion 438-40. PubMed ID: 17447832
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Clinical characteristics of restless legs syndrome in end-stage renal failure and idiopathic RLS patients.
    Enomoto M; Inoue Y; Namba K; Munezawa T; Matsuura M
    Mov Disord; 2008 Apr; 23(6):811-6; quiz 926. PubMed ID: 18074382
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Entacapone prolongs the reduction of PLM by levodopa/carbidopa in restless legs syndrome.
    Polo O; Ylä-Sahra R; Hirvonen K; Karvinen J; Vahteristo M; Ellmén J
    Clin Neuropharmacol; 2007; 30(6):335-44. PubMed ID: 18090458
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Immobilization tests and periodic leg movements in sleep for the diagnosis of restless leg syndrome.
    Montplaisir J; Boucher S; Nicolas A; Lesperance P; Gosselin A; Rompré P; Lavigne G
    Mov Disord; 1998 Mar; 13(2):324-9. PubMed ID: 9539348
    [TBL] [Abstract][Full Text] [Related]  

  • 52. In vivo mesolimbic D2/3 receptor binding predicts posttherapeutic clinical responses in restless legs syndrome: a positron emission tomography study.
    Oboshi Y; Ouchi Y; Yagi S; Kono S; Nakai N; Yoshikawa E; Futatsubashi M; Terada T; Kim K; Harada K
    J Cereb Blood Flow Metab; 2012 Apr; 32(4):654-62. PubMed ID: 22234337
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Randomized trial of pramipexole for patients with restless legs syndrome (RLS) and RLS-related impairment of mood.
    Montagna P; Hornyak M; Ulfberg J; Hong SB; Koester J; Crespi G; Albrecht S
    Sleep Med; 2011 Jan; 12(1):34-40. PubMed ID: 20965780
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Pramipexole versus dual release levodopa in restless legs syndrome: a double blind, randomised, cross-over trial.
    Bassetti CL; Bornatico F; Fuhr P; Schwander J; Kallweit U; Mathis J;
    Swiss Med Wkly; 2011; 141():w13274. PubMed ID: 22101745
    [TBL] [Abstract][Full Text] [Related]  

  • 55. Compulsive habits in restless legs syndrome patients under dopaminergic treatment.
    Pourcher E; Rémillard S; Cohen H
    J Neurol Sci; 2010 Mar; 290(1-2):52-6. PubMed ID: 19969309
    [TBL] [Abstract][Full Text] [Related]  

  • 56. Decision-making, reward-seeking behaviors and dopamine agonist therapy in restless legs syndrome.
    Bayard S; Langenier MC; Dauvilliers Y
    Sleep; 2013 Oct; 36(10):1501-7. PubMed ID: 24082309
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Open-label study of the long-term efficacy and safety of pramipexole in patients with Restless Legs Syndrome (extension of the PRELUDE study).
    Partinen M; Hirvonen K; Jama L; Alakuijala A; Hublin C; Tamminen I; Koester J; Reess J
    Sleep Med; 2008 Jul; 9(5):537-41. PubMed ID: 18276187
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Efficacy of pergolide in treatment of restless legs syndrome: the PEARLS Study.
    Trenkwalder C; Hundemer HP; Lledo A; Swieca J; Polo O; Wetter TC; Ferini-Strambi L; de Groen H; Quail D; Brandenburg U;
    Neurology; 2004 Apr; 62(8):1391-7. PubMed ID: 15111679
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Efficacy of pramipexole in restless legs syndrome: a six-week, multicenter, randomized, double-blind study (effect-RLS study).
    Oertel WH; Stiasny-Kolster K; Bergtholdt B; Hallström Y; Albo J; Leissner L; Schindler T; Koester J; Reess J;
    Mov Disord; 2007 Jan; 22(2):213-9. PubMed ID: 17133582
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Is there a polysomnographic signature of augmentation in restless legs syndrome?
    Mitterling T; Frauscher B; Falkenstetter T; Gschliesser V; Ehrmann L; Gabelia D; Brandauer E; Poewe W; Högl B
    Sleep Med; 2014 Oct; 15(10):1231-40. PubMed ID: 25129261
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 21.